Dementia Assessment Panel

Description

Overview

• Dementia is a progressive condition that affects memory, thinking, and daily functioning. An estimated 7 million Americans aged 65 and older are currently living with some form of dementia—a number expected to grow significantly in the coming decades. While cognitive symptoms typically appear later in life, the underlying changes in the brain can begin years, even decades, earlier.
• Our dementia assessment panel analyzes a wide spectrum of gene variants associated with multiple types of cognitive degeneration. This comprehensive approach enables early risk identification—empowering providers and patients to take proactive, personalized steps to support brain health well before symptoms arise.

What This Test Covers

• Neurodegenerative Risk Genetics
  • Analyzes genetic susceptibility to hallmark mechanisms of cognitive decline
  • Susceptibility to Dementia
  • APOE Risk Susceptibility

• Microbiome–Cognitive Health Profile
  • Explores the genetic connection between gastrointestinal health and cognitive function
  • Gut-Brain Resilience

• Dementia’s Metabolic Risk Indicators
  • Evaluates genetic interactions between metabolic function and risk of dementia
  • Dementia’s Disease-Metabolic Interaction Susceptibility

• Homocysteine Regulation
  • Assesses the genetic ability to regulate homocysteine, a biomarker tied to oxidative stress and neurovascular damage
  • Hyperhomocysteinemia

• Neuro-Immune Health
  • Analyzes inflammatory response genes linked to brain degeneration
  • Chronic Inflammation Susceptibility

• Nutrient Metabolism Profiles
  • Evaluates metabolism of key neuroprotective nutrients
  • Zinc Metabolism Profile
  • Vitamin D Deficiency Susceptibility

Why It Matters

Early detection of genetic risk can be a game-changer allowing for preventive strategies that delay or reduce disease progression. The Dementia Assessment Panel helps address this urgency by offering:

Who Should Take This Test

• Adults with a family history of dementia seeking proactive risk assessment.
• Individuals experiencing early signs of cognitive decline or memory concerns.
• Functional and integrative medicine practitioners addressing brain aging at the root.
• Neurologists and dementia clinics integrating genomics into diagnostic protocols.
• Providers supporting patients with brain fog, emotional changes, or mood shifts.
• Anyone seeking to personalize brain health plans with precision-based insights.

What You’ll Receive

I. Comprehensive Genetic Report
Organized into clear categories and subcategories, covering key health areas with polygenic risk interpretations (Low, Medium, High) for each category.

II. Personalized Insights
Actionable insights for nutrition and supplement strategies, lifestyle modifications, and lab tests to consider for monitoring cognitive risk based on patients’ unique genetic profile.

Turnaround Time

Results will be available approximately 2 weeks from the receipt of the sample and will be securely delivered through the Provider Portal, enabling seamless access, viewing, and sharing of reports.

Collection Method

The Testing Me kits include all necessary self-collection devices for non-invasive, at-home saliva collection, making it easy to deliver real-time, data-driven healthcare solutions without the need for lab visits.